Skip to content
2000
Volume 18, Issue 2
  • ISSN: 1574-888X
  • E-ISSN: 2212-3946

Abstract

HIV is a virus that targets and hijacks the immune cells of the host. It multiplies by attacking the helper T-lymphocytes. HIV has remained one of the most difficult and dangerous infections in the world due to the inability to find a successful treatment and a lack of access to medical care. When the virus reaches the body, dendritic cells are the first cells it encounters. DCs have been identified as one of the most effective mediators of immune responses, implying a promising strategy against viral infection. The current state of knowledge about the function of dendritic cells and their subsets is critical for using their full potential as a candidate for the development of an HIV vaccine. Despite extensive efforts, a reliable vaccine with the fewest side effects has yet to be found, and further research is needed to find a dependable and efficient vaccine. The extent to which dendritic cell-based therapy is used to treat HIV was investigated in this study. As the virus attacks the host immune system, the dendritic cells can trigger an immune response against HIV-1 infection.

Loading

Article metrics loading...

/content/journals/cscr/10.2174/1574888X17666220401102718
2023-02-01
2024-11-14
Loading full text...

Full text loading...

/content/journals/cscr/10.2174/1574888X17666220401102718
Loading

  • Article Type:
    Review Article
Keyword(s): cell-based therapy; Dendritic cells; HIV; immune system; T-lymphocytes; vaccine
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test